Biomarkers-specific antibodies are valuable diagnostic tools to improve the sensitivity and specificity of cancer diagnosis and prognosis. By combining advanced technologies and long-term scientific expertise in the field of antibody discovery, Creative Biolabs offers unparalleled in vitro diagnostic (IVD) antibody & immunoassay development services targeting a wide range of disease biomarkers, such as mammaglobin.
Mammaglobin is a small breast-associated glycoprotein (93 amino acids, approximately 10 kDa) with homology to other secretoglobin-uteroglobin family members. Mammaglobin proteins possess two members, A (MGB1) and B (MGB2), both of them contain an alpha-helix in the structure and are often found as dimers. MGB1 and MGB2 share 58% homology and are thought to perform the same biological functions. MGB2 is overexpressed in ovarian and endometrium cancers, as well as all primary and metastatic breast cancers. In contrast, MGB1 overexpression is only limited to breast cancer. MGB1 and MGB2 have been reported as markers of breast cancer micro-metastases to lymph nodes and markers of circulating tumor cells (CTCs) found in the blood of breast cancer patients.
Fig.1 Pro-tumor and anti-tumor activities of mammaglobin-A.1
Breast cancer is a lethal disease with a high fatality rate and short survival especially in patients with advanced disease. Presently, mammaglobin has become one of the most specific markers for breast cancer and the detection of CTCs and micrometastasis. In breast cancer, mammaglobin has been found in primary and metastatic lesions, lymph node metastases, and CTCs. Additionally, it is believed that mammaglobin has a role in cancer development, immune system regulation, and the transport of aromatic molecules, such as steroid hormones. Therefore, the development of highly specific recognition antibodies against mammaglobin will aid in the diagnosis of breast cancer and CTCs from breast cancer tumors. Besides, mammaglobin-based strategies for the treatment of breast carcinoma have attracted numerous interests, for example, by targeting breast carcinomas with toxin-conjugated mammaglobin antibodies, mammaglobin-targeted immune therapy, and gene therapy vectors with the mammaglobin promoter driving Bax expression resulting in apoptosis of the breast carcinoma cells.
Mammaglobin has been combined with many other breast cancer markers to increase diagnostic specificity. IVD antibodies against the mammaglobin marker present an independent prognostic and diagnostic value in breast cancer patients. With state-of-the-art equipment and years of experience, Creative Biolabs can provide antibody discovery and development services for clinical diagnosis. These antibodies can be customized for the development of different immunoassay formats, including ELISAs, immunohistochemistry, western blot, etc. With our versatile IVD platform, Creative Biolabs is proud to develop novel mammaglobin-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates). For more detailed information about what we offer for each stage of the development process, please click the links below:
Please feel free to contact us for more information and discuss your project needs.
Reference
For Research Use Only.
